-- 週五，西德克薩斯中質原油（WTI）價格收跌，此前伊朗提出新的和平方案，但美國總統川普拒絕了該方案。 6月交割的WTI原油期貨價格下跌3.13美元，收在每桶101.94美元；7月交割的布蘭特原油期貨價格下跌2.177美元，收在每桶108.23美元。 路透社報道稱，伊朗提出了與美國達成和平協議的新方案。儘管細節尚未披露，但川普拒絕了該方案，並告訴記者他對方案並不滿意。不過，他證實，由巴基斯坦斡旋的間接會談仍在繼續，雙方透過電話進行磋商。 由於霍爾木茲海峽關閉，石油供應仍短缺。霍爾木茲海峽是波斯灣國家石油出口的咽喉要道，這些國家的石油出口占每日需求的20%。自2月28日戰爭爆發以來，原油和成品油供應短缺導致原油價格上漲超過一半，紐約商品交易所（Nymex）汽油期貨價格自戰爭爆發以來上漲了81%，而航空燃油供應也日益緊張。 供應緊張的局面正值5月23日陣亡將士紀念日長週末到來之際，而這通常是夏季駕車出行旺季的開始，屆時燃油需求將達到高峰，這可能會進一步推高油價。 加拿大皇家銀行資本市場全球大宗商品策略及中東和北非研究主管赫利瑪·克羅夫特（Helima Croft）寫道：「隨著夏季需求旺季的臨近，我們認為油價預計將超過2022年甚至2008年的高點，尤其是在市場對霍爾木茲海峽封鎖轉變持續時間的看法可能最終發生的情況下。」
Related Articles
Research
Research Alert: CFRA Lowers View On Bio-rad Laboratories To Sell From Hold
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $45 to $235, reflecting a 25.6x multiple of our 2026 EPS estimate (down to $9.17 from $10.15; we cut our 2027 EPS estimate to $9.97 from $10.68), a discount to BIO's three-year historical forward average of 29.5x. Rather than a dramatic cut to National Institutes of Health (NIH) funding, Congress approved a modest increase for 2026 funding, helping reduce research budget concerns that loomed during 2025. However, BIO and peers anticipate that research spending growth from academic and early-stage biotech could remain muted over the near term as academic institutions adjust. The outlook for 2026 anticipates ongoing pressure, with BIO cutting sales and margin expectations during the Q1 earnings report, citing headwinds arising from the U.S.-Iran conflict in the Middle East such as weaker diagnostics sales and higher freight and fuel costs.
$BIO
Research
Research Alert: CFRA Maintains Hold Rating On Shares Of Dexcom, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $1 to $67, 26.1x our 2026 EPS estimate (up $0.08 to $2.57; 2027 estimate up $0.06 to $3.05), below DXCM's one-year historical forward average of 34.2x and well below the three-year average of 56.6x, to reflect stronger competition within the continuous glucose monitoring space and uncertain insurance coverage and rebate dynamics, in our view. DXCM recently launched the G7 15-day continuous glucose monitoring (CGM) system in the U.S., which offers users a longer-wear time between devices and increased accuracy, per DXCM. The company expects close to half of its U.S. base to convert to the new device by year-end 2025. We think the addressable market for DXCM is large and far from saturated, but a slower sales growth rate is a concern, which we attribute to market share losses and slow progress in gaining additional insurance coverage approvals.
$DXCM
Research
Research Alert: CFRA Keeps Hold Opinion On Shares Of Chevron Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target of $211, up $5, reflects EV/EBITDA and DCF analyses. We apply an 8.0x multiple of EV to projected 2027 EBITDA, above CVX's historical forward average, but below peak levels, yielding $186 per share. Our DCF model, using FCF growth of 7.1% per year for 10 years and 2.5% thereafter, discounted at 6.0%, yields $237 per share. We cut our 2026 EPS estimate by $0.14 to $11.16 and our 2027 estimate by $0.39 to $8.93. CVX suffered some volume degradation in international upstream in Q1, as the war in the Middle East has disrupted the normal course of business. We note, however, that this degradation was less acute for CVX than for its chief rival, Exxon Mobil (XOM 153 ***). CVX maintained a conservative approach to spending in Q1 despite the ramp in crude prices, as we estimate that its reinvestment rate was just 44% in Q1, about on par with that of XOM at 43%. Shares yield 3.7%, and we see a healthy degree of buyback activity as well.
$CVX